FFAR3 and diabetes mellitus: Other studies have reported that SCFAs can promote the release of glucagon-like peptide-1 from enteroendocrine L cells through GPR41/43-dependent mechanisms, which highlights SCFAs as a potential target for the treatment of DM (Tolhurst et al., 2012; Everard and Cani, 2014; Kaji et al., 2014).